![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Assessing the Real-World Effectiveness and
Clinical Efficacy of 8198 Patients Receiving
Elbasvir/Grazoprevir for the Treatment of HCV Infection
|
|
|
AASLD 2019 Nov 8-11 Boston
Jennifer R. Kramer1,2; Amy Puenpatom3; Barbara A. Haber3; Peggy Hwang3; Xian Yu1,2; Fasiha Kanwal1,2
1Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX;
2Department of Medicine, Baylor College of Medicine, Houston, TX; 3Merck & Co., Inc., Kenilworth, NJ
![0203201](../images/020320/020320-1/0203201.gif)
![0203202](../images/020320/020320-1/0203202.gif)
![0203203](../images/020320/020320-1/0203203.gif)
![0203204](../images/020320/020320-1/0203204.gif)
![0203205](../images/020320/020320-1/0203205.gif)
![0203206](../images/020320/020320-1/0203206.gif)
![0203207](../images/020320/020320-1/0203207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|